Description

The 10th Ocular Diseases Drug Discovery Conference is taking place on March 20-21, 2021 in San Diego, CA. We are excited to have top representatives from the industry and academic sectors to discuss technologies and targets that are continually changing the way ocular diseases are treated. Drug delivery is always improving as we look at for better methods to penetrate anterior and poster segments of the eye. Successes in gene therapy and regenerative medicine are proving to be interesting approaches to discuss in detail pre-clinically and clinically. We are gathering leading scientists, researchers, and experts to discuss and collaborate on combating and curing age-related macular degeneration (AMD), dry eye, glaucoma, diabetic macular edema (DME), and other ocular diseases.

Session Topics

1. Opening Keynote Session: Historical Perspective and State of the Industry
2. Preclinical Development of Novel Technologies
3. Translational Studies and Lessons Learned
4. Partnering with Academia and CROs to Advance Research
5. Panel on Funding
6. Panel on Regulatory Challenges
7. Closing Keynote Session: Predictions for Future

Day 1 - Monday, March 20th, 2017

7:00 Continental Breakfast & Registration

8:15 Welcome & Opening Remarks
KEYNOTE PLENARY SESSION 
Brian Levy, Ocunexus Therapeutics 

8:30 Vision Restoration Initiative: Retinal Organoid Implants Development
Oscar Cuzzani Oscar Cuzzani 
Vice President, Clinical Development
BioTime

9:15 Systemic, Targeted Nanotherapies for Ocular Disorders
Kannan Rangaramanujam Kannan Rangaramanujam 
Co-director of the Center for Nanomedicine
John Hopkins

Abstract: Inflammation, mediated by activated microglia/macrophages (mi/ma), plays a key role in the pathogenesis of both geogra...Read More 

10:00 Morning Networking Break
Novel Therapeutic Targets for Ocular Diseases 
Stuart Williams, Envisia Therapeutics 

10:30 New Targets and Treatment Strategies in Hypertensive Glaucoma
David Krizaj David Krizaj 
Professor; Dept. of Ophthalmology & Visual Sciences
Moran Eye Center, University of Utah School of Medicine

Abstract: Elevated intraocular pressure (IOP), a major risk factor in glaucoma, is associated with increased production and/or d...Read More 

10:55 CFTR Chloride Channel Activators for Pro-Secretory Therapy of Dry Eye Diseases
Alan Verkman Alan Verkman 
Professor of Medicine & Physiology
UCSF

Abstract: CFTR (cystic fibrosis transmembrane conductance regulator) is a cAMP-gated chloride channel expressed in ocular surface epithelial where it functio...Read More 

11:20 Novel Technologies Provide a Comprehensive In-Vivo Assessment of the Eye
Christine van Hover Christine van Hover 
Chief Scientist
Phoenix Research Labs

Abstract: Technologies developed in the last eight years are revolutionizing eye and eye-brain studies using laboratory animals....Read More 

11:45 Patient-Centered Solutions - Improving Clinical Studies
Michael Tucker Michael Tucker 
Director, Business Development
Mytrus, Inc.

Abstract: “Patient-Centered” is a term that is often misused in research today. Patient-centered solutions should help the patient feel mor...Read More 

12:10 Lunch Provided by GTCbio
Novel Therapeutic Target for Ocular Diseases (cont.) 
David Krizaj, Moran Eye Center, University of Utah School of Medicine 

1:15 Novel Glaucoma Treatment Options
Naj Sharif Naj Sharif 
Executive Director in Global R&D Head, Global Alliances & External Research (GAER); (former Head, Global Biomedical Sciences)
Santen Incorporated

Abstract: Glaucoma is a blinding disease encompassing a multitude of retinal / optic neuropathies. Primary open angle glaucoma (...Read More 

1:40 Connexin43 (Cx43) and the Inflammasome Pathway; Effective Therapeutic Targets in Serious Eye Disease
Brian Levy Brian Levy 
Chief Executive Officer
Ocunexus Therapeutics

Abstract: Purpose: In chronic back of the eye disease the inflammasome pathway is triggered by overexpression of Cx43, hemichannel (HC) pathology releasing&n...Read More 

2:05 Antisense Oligonucleotides for Treatment of adRP
Michael McCaleb Michael McCaleb 
Vice President
Ionis Pharmaceuticals

Abstract: A new generation of antisense oligonucleotides (ASO) has demonstrated a broad utility for the treatment of ophthalmic ...Read More 

2:30 Old Targets Become New Again: Multi-Targeting PG Receptors for Therapeutic Benefits
Neil Poloso Neil Poloso 
Director, Biological Research
Allergan

Abstract: The concept of poly-pharmacology, specifically a single drug for multiple targets, is currently drawing increased atte...Read More 

2:55 Afternoon Networking Break
Stem Cell and Gene Therapy for Ocular Diseases 
Andreas Lauer, Casey Eye Institute - Oregon Health & Science University 

3:25 Zika Virus Infection of Cellular Components of the Blood Retinal Barriers: Implications for Viral Associated Congenital Ocular Disease
Donald Alcendor Donald Alcendor 
Associate Professor
Meharry Medical College

Abstract: Ocular abnormalities present in microcephalic infants with presumed Zika virus (ZIKV) congenital disease includes foca...Read More 

3:50 Surgical Considerations in the Delivery of Genes and Cells for Retinal Disease
Andreas Lauer Andreas Lauer 
Kenneth C. Swan Professor of Ophthalmology and Vice-Chair for Education
OHSU

Abstract: Casey Eye Institute at Oregon Health & Science University is engaged in pre-clinical and human clinical trials involving the delivery of gene a...Read More 

4:15 Optogenetic Therapy for Retinitis Pigmentosa
Lukas Scheibler Lukas Scheibler 
EVP & Head R&D
Acucela Inc.

Abstract: Retinitis Pigmentosa (RP) is an inherited, retinal dystrophy wherein progressive photoreceptor degeneration blinds pat...Read More 

4:40 Networking Reception & Poster Session

Day 2

Day - 2 Tuesday, March 21st, 2017

7:30 Continental Breakfast
Panel Discussion: Business Development and Partnering 
Donald Alcendor, Meharry Medical College, Vanderbilt University Medical Center 

8:30 Emmett Cunningham Emmett Cunningham 
Partner
Clarus Ventures

8:30 Lukas Scheibler Lukas Scheibler 
EVP & Head R&D
Acucela Inc.

8:30 MaryJane Rafii MaryJane Rafii

Independent

Recent Developments in Drug Delivery for Ocular Diseases 
Sina Fateh, Kali Care 

9:20 Patient Adherence and Compliance in Eye Care
Matthias Birkhoff Matthias Birkhoff 
Vice President Marketing
Aptar

Abstract: Poor patient compliance with drug dosing regimens can be a major impediment to effective treatments. Eye Care diseases...Read More 

9:45 Extended Release Intraocular Implants
Stuart Williams Stuart Williams 
Director of Research
Envisia Therapeutics, Inc.

Abstract: An important aspect of ocular drug delivery is the ability to (1) minimize monthly IVT injections and (2) improve pati...Read More 

10:10 Morning Networking Break

10:55 Ming Yang Ming Yang 
Director of Research
Graybug Vision

11:20 CANCELLED PRESENTATION: Ocular Drug Delivery Nanowafer – Design and Applications
Ghanashyam Acharya Ghanashyam Acharya 
Assistant Professor, Department of Ophthalmology
Baylor College of Medicine

Abstract: Ocular drug delivery, although seems deceptively simple is a challenging task mainly because of the unique barriers as...Read More 
Round Table Discussions

11:45 Round Table 1: Ocular Diseases Clinical Trails: Site Selection Criteria

11:45 Round Table 2: Funding Avenues and Trends

12:35 Lunch Provided by GTCbio
Recent Developments in Drug Delivery for Ocular Diseases (cont.) 
Sina Fateh , Kali Care 

1:45 The Impact of Digital Eyedrop and Big Data on Medication Adherence
Sina Fateh Sina Fateh 
CEO
Kali Care

Abstract: Poor medication adherence in ophthalmology is common. Studies have shown that on average, 50 percent of medications for glaucoma are not taken....Read More 
Panel Discussion: Patient Adherence and Compliance 
Michael Tucker, Mytrus, Inc. 

2:10 Panel Discussion Presentation Slides
Sina Fateh Sina Fateh 
CEO
Kali Care

2:10 Andreas Lauer Andreas Lauer 
Kenneth C. Swan Professor of Ophthalmology and Vice-Chair for Education
OHSU

2:10 Matthias Birkhoff Matthias Birkhoff 
Vice President Marketing
Aptar

2:55 Afternoon Networking Break
Combination Therapies for Ocular Diseases 
Ghanashyam Acharya, Baylor College of Medicine 

3:45 From Bench to Clinic: A Combination Treatment Approach Using Suprachoroidal CLS-TA and Intravitreal Aflibercept
Donna Taraborelli Donna Taraborelli 
Senior Director Corporate Development
Clearside Biomedical, Inc.

Abstract: Clearside is developing first-in-class pharmacological therapies for the treatment of posterior segment eye diseases. ...Read More 

4:10 Evaluation of Aflibercept in a Laser-Induced Model of Choroidal Neovascularization in Pigs
David Culp David Culp 
Director of Research
Powered Research

Abstract: The purpose of this study was to evaluate and characterize a porcine model of laser induced choroidal neovascularizati...Read More 
Panel Discussion: Leveraging CROs to Externalize R&D 
Christine van Hover, Phoenix Research Labs 

4:35 Brian Levy Brian Levy 
Chief Executive Officer
Ocunexus Therapeutics

4:35 David Culp David Culp 
Director of Research
Powered Research

4:35 Neil Poloso Neil Poloso 
Director, Biological Research
Allergan

4:35 Kannan Rangaramanujam Kannan Rangaramanujam 
Co-director of the Center for Nanomedicine
John Hopkins

4:35 Claire Gelfman Claire Gelfman 
Senior Director, Scientific Services
Ora, Inc.

5:00 Conference Concludes

--------------------------------
KEYNOTE SPEAKERS
--------------------------------

Jerry Cagle 
Independent Pharmaceuticals Professional

Carl Romano 
Executive Director, Ophthalmology
Regeneron

-----------------------------------------
DISTINGUISHED SPEAKERS
-----------------------------------------

Matthias Birkhoff 
Vice President Marketing
Aptar Pharma

Larry Brown 
Chief Scientific Officer
Noveome Biotherapeutics, Inc.

Jonca Bull 
VP, Regulatory Consulting; Ophthalmology Therapeutic Area Director
PPD

Emmett Cunningham 
Partner
Clarus Ventures

Mala Dutta 
Lead, Office of Translational Research
NEI, NIH

Rafal Farjo 
Founder and Chief Executive Officer
EyeCRO LLC

Mohamed Genead 
Chief Medical Officer
GenSight Biologics

Judy Gordon 
Founder & President
ClinReg Consulting Services, Inc

Pablo Gurman 
Chief Medical Officer
GearJump Technologies

Brian Levy 
Chief Executive Officer
Ocunexus Therapeutics

Charlie McDermott 
President & Chief Business Officer
Impact Biomedicines, Inc.

Neil Poloso 
Director, Biological Research
Allergan

Christian Roesky 
CEO & Managing Director
Novaliq

Derek Welsbie 
Assistant Professor, Ophthalmology
University of California, San Diego

Daniel White 
CEO
Clearside Biomedical

Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for: 
- Discounts for multiple participants.
- Require a price quotation.
- Require to pay by wire transfer or PayPal
- Invitation letter for visa applications

NO REFUNDS ALLOWED ON REGISTRATIONS 
-----------------------------------------------------------------
This Event is Brought to You by: 
GTCbio - NewYorkEventsList
http://www.NyEventsList.com
http://www.BostonEventsList.com
http://www.SFBayEventsList.com

MYL171011CEV MYL171025UPD CHA171109UPT